Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma
| العنوان: | Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma |
|---|---|
| المؤلفون: | Thorsten D. Poeppel, Kim M. Pabst, Sarah Theurer, Nicole Unger, Lale Umutlu, Walter Jentzen, Frank Weber, Wolfgang P. Fendler, Ken Herrmann, Jochen Schmitz, Martin K. Walz, Manuel Weber, Christoph Rischpler, Ines Maric |
| المصدر: | Journal of Nuclear Medicine. 63:869-874 |
| بيانات النشر: | Society of Nuclear Medicine, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | PET-CT, medicine.diagnostic_test, business.industry, M-Iodobenzylguanidine, medicine.disease, Scintigraphy, Pheochromocytoma, Paraganglioma, Positive predicative value, Radionuclide therapy, Medicine, Radiology, Nuclear Medicine and imaging, In patient, business, Nuclear medicine |
| الوصف: | 123/131I-MIBG scintigraphy has shown a high specificity for imaging pheochromocytoma and paraganglioma however with low sensitivity due to low spatial resolution. 124I-MIBG PET may overcome this limitation to improve the staging of patients with (suspected) pheochromocytoma. Methods: We analyzed the sensitivity, specificity, positive and negative predictive values (PPV, NPV) of 124I-MIBG PET in 43 consecutive patients with suspected (recurrence of) pheochromocytoma using histopathological (n = 25) and clinical validation (n = 18) as standard of truth. Furthermore, we compared 124I-MIBG PET versus contrast enhanced CT (CE-CT) per-patient and per-lesion detection rate of 124I-MIBG PET in 13 additional patients with known metastatic malignant pheochromocytoma (MMP). Results:124I-MIBG PET/CT was positive in 19/43 (44%) patients with suspected pheochromocytoma. Presence of pheochromocytoma was confirmed in 22/43 (51%). 124I-MIBG PET/CT sensitivity, specificity, PPV, NPV were 86%, 100%, 100%, 88%, respectively. 124I-MIBG PET was positive in 11/13 (85%) MMP patients. Combined 124I-MIBG PET and CE-CT detected 173 lesions, of which 166 (96%) and 118 (68%) were visible on 124I-MIBG PET and CE-CT, respectively. Discussion:124I-MIBG PET detects pheochromocytoma with high accuracy at initial staging and high detection rate at re-staging. Superior diagnostic performance aids guidance of surgical and medical management including personalized 131I-MIBG therapy. |
| تدمد: | 2159-662X 0161-5505 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::41b2a47ba9745dbd976eec1048e8d402 https://doi.org/10.2967/jnumed.121.262797 |
| رقم الأكسشن: | edsair.doi...........41b2a47ba9745dbd976eec1048e8d402 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2159662X 01615505 |
|---|